Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug access for Hard-to-Treat blood cancer patients

NCT ID NCT05269771

NO_LONGER_AVAILABLE Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This program offers ruxolitinib (Jakavi) to people aged 12 and older with polycythemia vera, a blood cancer that causes too many red blood cells. It is for patients whose disease has not responded to or who cannot take standard treatments like hydroxyurea. Participants take daily tablets at home under their doctor's guidance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ruxolitinib (also known as Jakavi)
What this could lead to
If successful, this program could provide a treatment option for polycythemia vera patients who have not responded to or cannot tolerate standard therapies.
What could go wrong
This is an access program, not a formal trial, so it does not test whether ruxolitinib works better than other options. Results may not apply to all patients, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POLYCYTHEMIA VERA

Contacts and locations

Locations

  • Novartis Investigative Site

    Orange, New South Wales, 2800, Australia

  • Novartis Investigative Site

    Leuven, 3000, Belgium

  • Novartis Investigative Site

    Calgary, Alberta, T2N 2T9, Canada

  • Novartis Investigative Site

    Tehran, 11367, Iran

  • Novartis Investigative Site

    Kfar Saba, Israel, 44281, Israel

  • Novartis Investigative Site

    Kfar Saba, 44281, Israel

  • Novartis Investigative Site

    Rehovot, 7610001, Israel

  • Novartis Investigative Site

    Tel Aviv, 6423906, Israel

  • Novartis Investigative Site

    Tel Giborim Holon, 58100, Israel

  • Novartis Investigative Site

    Groningen, 9700RB, Netherlands

  • Novartis Investigative Site

    Gdansk, 80-214, Poland

  • Novartis Investigative Site

    Katowice, 40-027, Poland

  • Novartis Investigative Site

    Krakow, 31-501, Poland

  • Novartis Investigative Site

    Warsaw, 00-791, Poland

  • Novartis Investigative Site

    Warsaw, 04-141, Poland

  • Novartis Investigative Site

    Wałbrzych, 58-309, Poland

  • Novartis Investigative Site

    Wroclaw, 50-367, Poland

  • Novartis Investigative Site

    Hereford, HR1 2ER, United Kingdom

  • Novartis Investigative Site

    Kent, CT9 4AN, United Kingdom

  • Novartis Investigative Site

    London, NW3 2PF, United Kingdom

  • Novartis Investigative Site

    London, SE5 8AD, United Kingdom

  • Novartis Investigative Site

    London, WC1E 6HX, United Kingdom

  • Novartis Investigative Site

    Oxford, OX3 7LJ, United Kingdom

  • Novartis Investigative Site

    Poole, BH15 2JB, United Kingdom

  • Novartis Investigative Site

    Salisbury, SP2 8BJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.